12 Best Small-Cap Healthcare Stocks To Buy Now

Published on December 12, 2022 at 3:44 pm by Hamna Asim in Hedge Funds, News

In this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now.

Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022. As per PwC, growing transaction volumes and market players focusing on value-based care, paired with high levels of cash stockpiles and private equity “dry powder”, are resulting in ongoing expansion for deal volumes in 2023. Nick Donkar, PwC’s U.S. health services deals leader, expects a resilient outlook for health services M&A activity in 2023 with companies majorly exploring M&A, divestitures, and similar transactions. Donkar stated in an interview on December 8:

“The deal market in 2022 was fairly robust coming off an unprecedented banner year, which was 2021. Obviously, 2021 was the highest deal volume we’ve experienced from a health services perspective. We’re happy to see the health of the overall market, no pun intended, with respect to the level of volume and activity that has been exhibited thus far in 2022.”

Nick Donkar categorized the healthcare space as almost “recession-proof“, noting that innovation, technological advancements, and high investment continues to improve patient care. Investors usually gravitate towards healthcare stocks like AbbVie Inc. (NYSE:ABBV), UnitedHealth Group Incorporated (NYSE:UNH), and Abbott Laboratories (NYSE:ABT). However, we discuss some of the top small-cap healthcare stocks in this article.

Our Methodology

We selected the following healthcare stocks based on positive analyst coverage, strong business fundamentals, and market visibility. These firms have a market cap of between $300 million to $2 billion as of December 12. We have assessed the hedge fund sentiment from Insider Monkey’s database of 920 elite hedge funds tracked as of the end of the third quarter of 2022.

Photo by National Cancer Institute on Unsplash

Best Small-Cap Healthcare Stocks to Buy Now

12. Addus HomeCare Corporation (NASDAQ:ADUS)

Number of Hedge Fund Holders: 10

Market Capitalization as of December 12: $1.662 Billion

Addus HomeCare Corporation (NASDAQ:ADUS) is a Texas-based company that provides personal care services to the elderly, chronically ill, disabled persons, and individuals at risk of hospitalization in the United States. It operates through three segments – Personal Care, Hospice, and Home Health. It is one of the best healthcare stocks to consider.

RBC Capital analyst Frank Morgan on November 2 raised the price target on Addus HomeCare Corporation (NASDAQ:ADUS) to $121 from $110 and maintained an Outperform rating on the shares. The company’s Q3 results were “solid” as organic Personal Care segment volume growth of 7% outperformed management’s expectations, the analyst told investors in a research note. He added that he is also encouraged by signs of a feasible hospice backdrop in October, as well as Addus HomeCare Corporation (NASDAQ:ADUS)’s improved hiring.

According to Insider Monkey’s data, 10 hedge funds were bullish on Addus HomeCare Corporation (NASDAQ:ADUS) at the end of September 2022, compared to 13 funds in the prior quarter. The collective stakes held by elite funds in Q3 2022 increased to $45 million from $44 million in Q2 2022. Brian Ashford-Russell and Tim Woolley’s Polar Capital held the largest position in the company, comprising 346,297 shares worth $33 million.

Like AbbVie Inc. (NYSE:ABBV), UnitedHealth Group Incorporated (NYSE:UNH), and Abbott Laboratories (NYSE:ABT), Addus HomeCare Corporation (NASDAQ:ADUS) is one of the best healthcare stocks to invest in.

11. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Number of Hedge Fund Holders: 11

Market Capitalization as of December 12: $1.914 Billion

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a California-based surgical robotics company that manufactures transformative solutions in urology. It develops and sells AquaBeam Robotic System, an image-guided, surgical robotic system for minimally-invasive urologic surgery focused on treating benign prostatic hyperplasia. On November 3, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) posted a Q3 revenue of $20.35 million, up 134.7% year-over-year, beating Wall Street estimates by $3.12 million. The company increased fiscal year 2022 total revenue guidance to approximately $72.5 million, representing growth of 110% compared to 2021, versus a consensus of $67.51 million.

On November 14, Truist analyst Richard Newitter raised the price target on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) to $58 from $56 and maintained a Buy rating on the shares. The analyst’s meeting with PROCEPT BioRobotics Corporation (NASDAQ:PRCT) management offered positive takeaways as the company believes it has a good handle on the two main issues that led to the FY22 guide down. The company’s CEO also indicated a high level of confidence that the impact from these issues is temporary and should be largely resolved by early 2023 or sooner, the analyst told investors in a research note.

According to Insider Monkey’s Q3 data, 11 hedge funds were bullish on PROCEPT BioRobotics Corporation (NASDAQ:PRCT), compared to 12 funds in the preceding quarter. Richard Driehaus’ Driehaus Capital is the leading position holder in the company, with 870,874 shares worth $36 million.

10. Krystal Biotech, Inc. (NASDAQ:KRYS)

Number of Hedge Fund Holders: 15

Market Capitalization as of December 12: $1.829 Billion

Krystal Biotech, Inc. (NASDAQ:KRYS) is a Pennsylvania-based clinical stage biotechnology company that specializes in redosable gene therapy to treat serious rare diseases in the United States. It is one of the best healthcare stocks to consider. On November 17, Krystal Biotech, Inc. (NASDAQ:KRYS)’s Jeune Aesthetics subsidiary announced that phase 1 data from an extension cohort indicated that KB301, a gene-based treatment developed to address the underlying biology of aging skin to treat wrinkles and fine lines, indicated durability over nine months. Jeune now plans to start a phase 2 study of KB301 in H1 2023.

On November 7, Chardan analyst Geulah Livshits raised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $133 from $130 and kept a Buy rating on the shares. Following Q3 results, the analyst noted that Krystal Biotech, Inc. (NASDAQ:KRYS) now expects to continue patient dosing with topical KB105 in the next cohort of the Phase II in TMG1-mediated ARCI in early 2023.

According to Insider Monkey’s third quarter database, Krystal Biotech, Inc. (NASDAQ:KRYS) was part of 15 hedge fund portfolios, compared to 12 in the prior quarter. The combined stakes held by elite funds in Q3 2022 increased to $389 million from $386.4 million in Q2 2022. Jeremy Green’s Redmile Group is the biggest stakeholder of the company, with approximately 2 million shares worth $132.4 million.

9. Nuvalent, Inc. (NASDAQ:NUVL)

Number of Hedge Fund Holders: 15

Market Capitalization as of December 12: $1.75 Billion

Nuvalent, Inc. (NASDAQ:NUVL) was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. It is a clinical stage biopharmaceutical company that develops therapies for patients with cancer. On October 28, Nuvalent, Inc. (NASDAQ:NUVL) reported initial data from the phase 1 part of a phase 1/2 trial of NVL-520 to treat patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors. The trial had a favorable safety profile and provided positive results. Nuvalent, Inc. (NASDAQ:NUVL) stock climbed 72% upon reporting the data. It is one of the best healthcare stocks to monitor.

On October 28, BMO Capital analyst Etzer Darout raised the price target on Nuvalent, Inc. (NASDAQ:NUVL) to $50 from $28 and kept an Outperform rating on the shares. The analyst cited the company’s initial dose escalation data for NVL-520, which he thinks serves as a clear indicator of its value proposition. Through the data cutoff, there were no treatment-related critical adverse events, the analyst told investors in a research note.

Among the hedge funds tracked by Insider Monkey, Nuvalent, Inc. (NASDAQ:NUVL) was part of 15 public stock portfolios at the end of September 2022, compared to 12 in the earlier quarter. James E. Flynn’s Deerfield Management is the largest stakeholder of the company, with 19.3 million shares worth $376 million.

8. Xencor, Inc. (NASDAQ:XNCR)

Number of Hedge Fund Holders: 16

Market Capitalization as of December 12: $1.755 Billion

Xencor, Inc. (NASDAQ:XNCR) is a California-based clinical stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. In Q3 2022, Xencor, Inc. (NASDAQ:XNCR) reported a revenue of $27.3 million, up 38.7% year-over-year, outperforming estimates by $6.25 million. The company expects to conclude 2022 with about $575 million to $600 million in cash, cash equivalents, receivables, and marketable debt securities. It is one of the best small-cap healthcare stocks to invest in.

On December 6, Cowen analyst Boris Peaker initiated coverage of Xencor, Inc. (NASDAQ:XNCR) with an Outperform rating without a price target. He forecasts Xencor, Inc. (NASDAQ:XNCR)’s partnered programs to generate revenue of up to $3 billion over the next decade from milestone and royalty payments, said the analyst, who also expects the company’s completely owned programs to “create further value as they advance.”

According to Insider Monkey’s Q3 data, 16 hedge funds were bullish on Xencor, Inc. (NASDAQ:XNCR), compared to 14 in the prior quarter. Oleg Nodelman’s EcoR1 Capital is the biggest stakeholder of the company, with 5.2 million shares worth $137.2 million.

7. Immunovant, Inc. (NASDAQ:IMVT)

Number of Hedge Fund Holders: 17

Market Capitalization as of December 12: $1.871 Billion

Immunovant, Inc. (NASDAQ:IMVT) is a New York-based clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of autoimmune diseases. On November 7, H.C. Wainwright analyst Douglas Tsao raised the price target on Immunovant, Inc. (NASDAQ:IMVT) to $17 from $16 and kept a Buy rating on the shares. The company had a “fairly uneventful earnings release after a period of significant activity,” the analyst told investors in a research note.

According to Insider Monkey’s data, Immunovant, Inc. (NASDAQ:IMVT) was part of 17 hedge fund portfolios at the end of the third quarter of 2022, with collective stakes worth $97 million, compared to 11 in the prior quarter worth $48.8 million. David Kroin’s Deep Track Capital is the leading position holder in the company, with 9.86 million shares worth $55 million.

6. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Number of Hedge Fund Holders: 18

Market Capitalization as of December 12: $1.705 Billion

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological diseases in the United States. On November 9, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reported a Q3 non-GAAP EPS of $0.26 and a revenue of $57.24 million, outperforming Wall Street estimates by $0.07 and $3.55 million, respectively. Revenue for the period climbed 59.2% on a year-over-year basis. The company also raised its full-year 2022 forecast for total revenues to be in the range of between $205 million and $210 million, representing a 46% to 49% increase compared to 2021, versus a consensus of $205.03 million.

On November 10, Piper Sandler analyst Joseph Catanzaro raised the price target on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to $18 from $16 and maintained an Overweight rating on the shares. The company reported Q3 Firdapse revenues of $57.2 million, which were well above consensus, and raised Firdapse revenue to $205 million-$210 million, the analyst told investors. Firdapse continues to grow, supported by a low discontinuation rate and organic growth, including higher enrollment of tumor-LEMS patients, the analyst added.

According to Insider Monkey’s Q3 data, 18 hedge funds were bullish on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), compared to 16 in the prior quarter. Jim Simons’ Renaissance Technologies is a prominent stakeholder of the company, with 2.2 million shares worth $28.5 million.

In addition to AbbVie Inc. (NYSE:ABBV), UnitedHealth Group Incorporated (NYSE:UNH), and Abbott Laboratories (NYSE:ABT), Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the top stocks to consider for exposure to the healthcare sector.

Click to continue reading and see 5 Best Small-Cap Healthcare Stocks To Buy Now.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

12 Best Small-Cap Healthcare Stocks To Buy Now

Published on December 12, 2022 at 3:44 pm by Hamna Asim in Hedge Funds, News

Best Small-Cap Healthcare Stocks to Buy Now

12. Addus HomeCare Corporation (NASDAQ:ADUS)

11. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

10. Krystal Biotech, Inc. (NASDAQ:KRYS)

9. Nuvalent, Inc. (NASDAQ:NUVL)

8. Xencor, Inc. (NASDAQ:XNCR)

7. Immunovant, Inc. (NASDAQ:IMVT)

6. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

12 Best Small-Cap Healthcare Stocks To Buy Now

Published on December 12, 2022 at 3:44 pm by Hamna Asim in Hedge Funds, News

Share

Best Small-Cap Healthcare Stocks to Buy Now

12. Addus HomeCare Corporation (NASDAQ:ADUS)

11. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

10. Krystal Biotech, Inc. (NASDAQ:KRYS)

9. Nuvalent, Inc. (NASDAQ:NUVL)

8. Xencor, Inc. (NASDAQ:XNCR)

7. Immunovant, Inc. (NASDAQ:IMVT)

6. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Share

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff